Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MENSIA Technologies has been awarded €3.6m from the EU as part of the H2020/SME Instrument call for projects, for its project NEWROFEED.
Subscribe to our email newsletter
The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD.
Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution NEWROFEED is based on neurofeedback training of the brain. It is used at home under medical supervision to:
Identify and quantify in real time abnormal brain activity in ADHD patients;
Personalize treatment with a care protocol adapted to each child;
Re-train the patients’ brain wave pattern for lasting normalization;
Monitor daily the child’s observance and progress during the programme.
Providing care in a familiar environment promotes the family’s involvement and hence the child’s willingness to comply with the treatment.
MENSIA Technologies CEO Jean-Yves Quentel said: "We are proud that our technology was selected for the EU programme Horizon 2020, one of the most selective programmes funding disruptive technological innovations.
"We will therefore accelerate the development of our medical device NEWROFEED: to demonstrate its efficacy, we will launch in 2016 a pan-European multicentre clinical study. Our alternative, non-invasive, non-drug treatment satisfies a major need in the etiological treatment of ADHD."